Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Says Bifeprunox Side Effect Profile Is Benefit Over Atypical Antipsychotics

This article was originally published in The Pink Sheet Daily

Executive Summary

NDA submission buoyed by four Phase III studies, including two involving active comparators.

You may also be interested in...



Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay

Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.

Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay

Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.

Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear

FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel